Medical Device for Nasal Congestion and Rhinitis: Clinical Results on Symptoms and Quality of Life
Nasal congestion is one of the most common respiratory disorders affecting both adults and children. It may be associated with allergic rhinitis, rhinosinusitis, the common cold, or environmental irritants, leading to nasal obstruction, discharge, facial pressure, sleep disturbances, and reduced quality of life.
According to the international guidelines EPOS 2020 (European Position Paper on Rhinosinusitis and Nasal Polyps) and the ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations, chronic nasal obstruction can significantly affect quality of life, impairing sleep, concentration, and work performance.
In this context, Rinofast was developed as a medical device for the treatment of nasal congestion and related symptoms, with a targeted action aimed at restoring the physiological function of the nasal mucosa.
Clinical Study on Rinofast: Methodology and Evaluation with Sino-Nasal Outcome Test
Gruppo FarmaImpresa conducted a prospective observational clinical study to evaluate the effectiveness of Rinofast in patients suffering from nasal congestion and symptoms compatible with rhinitis or rhinosinusitis.
Clinical evaluation was performed using the Sino-Nasal Outcome Test (SNOT-22), one of the most widely used and internationally recognized clinical questionnaires to measure nasal symptom severity and their impact on quality of life.
The SNOT-22 assesses 22 parameters related to:
- Nasal obstruction
- Rhinorrhea
- Sneezing
- Facial pain and pressure
- Smell disturbances
- Sleep disorders
- Emotional and functional impact
Higher scores indicate greater symptom severity.
Patients were assessed at baseline (T0) and at the end of treatment (T1), allowing measurement of clinical symptom variation.
Clinical Study Results: Significant Improvement in Nasal Symptoms
The clinical study results demonstrated a significant reduction in the total SNOT-22 score, indicating a clinically meaningful improvement in nasal congestion and associated symptoms.
In particular, the study showed:
- Reduction in nasal obstruction
- Improved breathing
- Decreased nasal discharge
- Improved sleep quality
- Reduced emotional burden related to symptoms
Statistical analysis confirmed the significance of the results (p < 0.001), demonstrating treatment effectiveness within a relatively short period.
Why Choose Rinofast for Nasal Congestion Treatment
Rinofast stands out for:
- Clinically proven efficacy measured with SNOT-22
- Targeted action on the nasal mucosa
- Improvement in quality of life
- Suitable for rhinitis, nasal congestion, and rhinosinusitis
The device represents an effective solution for managing nasal symptoms in both acute and subacute phases.
Indications for Use
Rinofast is indicated for:
- Nasal congestion
- Allergic and non-allergic rhinitis
- Rhinosinusitis
- Common cold
- Respiratory obstruction impacting sleep
Rinofast is available for international distribution in ready-to-market or private label format, with full regulatory and clinical support.
Looking for a B2B-ready or private label solution?
We are certified manufacturers of medical devices, dietary supplements, and cosmetics. Rinofast is ready for market entry or private labeling, with full regulatory and clinical support.
